| 1. |
Management of CAP reviewed |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
The EMEA*has issued a draft guideline on the filing of approval applications for pandemic influenza vaccines, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Levothyroxine plus liothyronine no aid to QOL in hypothyroidism |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Long-acting risperidone adds value in schizophrenia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 5-6
L Hunt,
Preview
|
|
摘要:
Atypical antipsychotics are the mainstay of therapy in the treatment of schizophrenia, due to their effective management of both positive and negative symptoms. However, relapses resulting from partial compliance with therapy can limit the clinical success of these agents. Treatment options in schizophrenia have been further limited by a lack of long-acting atypical antipsychotics. Researchers at the 6th European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Barcelona, Spain; November 2003] presented data that showed the potential for improved outcomes and cost savings following treatment with the first long-acting injectable atypical antipsychotic risperidone [Risperdal Consta] in patients with schizophrenia, schizoaffective disorder or other psychotic disorders.1,2
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Patient-controlled methylphenidate significantly improves fatigue and QOL among patients with advanced cancer, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Clobetasol foam enriches QOL in psoriasis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
NAPc2 prolongs survival in Ebola virus infection |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
HuMax-CD4*did not produce statistically significant results in the treatment of psoriasis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Desmopressin is effective and well tolerated in the treatment of women with nocturia, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
VALIANT: landmark study shows valsartan equal to captopril in MI |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 11-12
RM Poole,
Preview
|
|
摘要:
The angiotensin II receptor blocker (ARB) valsartan [Diovan] is as effective as the ACE inhibitor captopril in the treatment of patients with acute myocardial infarction (MI), according to results from a major international study presented at the 76th Annual Scientific Sessions of the American Heart Association [Orlando, US; November 2003] and subsequently published in TheNEJM. The VALIANT (VALsartan In Acute myocardial iNfarcTion) study showed that valsartan was as effective as captopril, a current standard therapy, in reducing all-cause mortality, cardiovascular-related mortality, recurrent MI and heart failure."It appears that[valsartan]will be especially beneficial in producing the same cardiovascular benefits as ACE inhibitors, thereby providing patients and clinicians with an effective alternative,"said Dr Marc Pfeffer from Brigham and Women's Hospital in Boston, US, who presented the study results."As a result of VALIANT, today there exists two proven, effective therapies to preserve life after a heart attack".
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
